Crossmark

Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma

Crossref DOI link: https://doi.org/10.1007/s11060-018-2775-y

Published Online: 2018-01-27

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Jiayi https://orcid.org/0000-0002-5153-506X
Campian, Jian L.

Gujar, Amit D.

Tsien, Christina

Ansstas, George

Tran, David D.

DeWees, Todd A.

Lockhart, A. Craig

Kim, Albert H.
License Information

Text and Data Mining valid from 2018-01-27
More Information

Article History

Received: 21 December 2017

Accepted: 22 January 2018

First Online: 27 January 2018

Compliance with ethical standards

:

: There are no conflict of interest relevant to this study. J.H. is the study chair of a clinical trial sponsored by Cantex Pharmaceuticals to reformulate disulfiram for recurrent glioblastoma (NCT03034135), outside of submitted work.

Document is current

Any future updates will be listed below